 "Sputnik")
Australia's Therapeutic Goods Administration (TGA) has recognized the two-dose course of the Russian Sputnik V vaccine against COVID-19 as an acceptable form of coronavirus vaccination for travellers.
"Today, the TGA determined that an additional COVID-19 vaccine, the two-dose course of the Gamaleya Institute vaccine (Sputnik V, Russian Federation) would be 'recognized' for the purpose of establishing a traveller's vaccination status," the TGA said in a Monday statement.
The regulator explained that additional data on the Russian vaccine's effectiveness showed that two doses of Sputnik V demonstrated an average efficacy against symptomatic COVID-19 infection of 89 percent and against hospitalization or death of 98-100 percent.
"The single-dose course of the Gamaleya vaccine ('Sputnik Light') is not currently recognized by the TGA," the Australian regulator specified.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
